The major obstacles of anti-PD
therapy in metastatic
tumors are limited drug delivery in primary
tumors and metastatic foci, and the lack of tumor-infiltrating lymphocytes (TILs). Here, the authors constructed a novel cellular membrane nanovesicles platform (M/IR NPs) based on homologous targeting and near-infrared (NIR) responsive release strategy to potentiate
PD-1/PD-L1 blockade therapy against metastatic
tumors. In
tumor-bearing mice, biomimetic M/IR NPs targeted both primary
tumors and their lung
metastases. Upon
laser irradiation, M/IR NPs reduced cancer-associated fibroblasts (CAFs) in tumor microenvironment, thus increasing the penetration of TILs. When shed from homologous
tumor cell membranes, positively charged nanoparticles (IR NPs) core can capture released
tumor-associated
antigens, thereby enhancing the
antigen-presenting ability of DCs to activate cytotoxic T lymphocytes. When the photothermal conversion temperature under NIR-
laser is higher than 42 °C, M/IR NPs initiated the
rupture of cell membranes and the responsive release of PD-1/
PD-L1 inhibitor BMS, which significantly attenuated
tumor-associated immunosuppression and synergistically induced T cellular immunity to inhibit the
tumor growth and
metastasis. Overall, biomimetic M/IR NPs can improve the targeting and therapeutic efficacy of anti-PD
therapy in primary
tumors and
metastases, opening up a new avenue for the diagnosis and treatment of metastatic
tumors in the future.